NCT04187872: LITT and Pembrolizumab in Recurrent Brain Metastasis

NCT04187872
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years ¬† (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must have 5 or less target metastatic lesions that are new or growing
Exclusions: 
https://ClinicalTrials.gov/show/NCT04187872

Comments are closed.

Up ↑